GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model

Ortiz, Didio Alberto; Peregrín, Nuria; Valencia, Miguel; Vinueza-Gavilanes, Rodrigo; Marin-Ordovas, Elisa; Ferrero, Roberto

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Ortiz, Didio Alberto
dc.contributor.author	Peregrín, Nuria
dc.contributor.author	Valencia, Miguel
dc.contributor.author	Vinueza-Gavilanes, Rodrigo
dc.contributor.author	Marin-Ordovas, Elisa
dc.contributor.author	Ferrero, Roberto
dc.date.accessioned	2025-01-22T11:42:11Z
dc.date.available	2025-01-22T11:42:11Z
dc.date.issued	2024-09-20
dc.identifier.citation	Ortiz DA, Peregrín N, Valencia M, Vinueza-Gavilanes R, Marín-Ordovas E, Ferrero R, et al. GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model. Transl Neurodegener. 2024 Sep 20;13:49.
dc.identifier.issn	2047-9158
dc.identifier.uri	https://hdl.handle.net/11351/12459
dc.description	Toxicitat; Model de ratolí; Esclerosi lateral amiotròfica
dc.description.sponsorship	This work was supported by PID2020‑120497RB‑I00 MCIU/AEI/https://doi.org/ 10.13039/501100011033, BFU2017‑90043‑P MCINN/AEI/https://doi.org/10. 13039/501100011033/ and by FEDER “Una manera de hacer Europa” (MA and TA), Proyecto Intramural IdisNa 2022 (MA), Fundación para la Investigación Médica Aplicada (FIMA) Proyectos I + D, 2017 (TA) and Fundación Occident and DalecandELA Association (MA). DO was supported by República de Panamá, Programa de Becas IFARHU‑SENACYT (reference number 270‑2018‑922), and NP by AC FIMA pre‑doctoral fellowship.
dc.language.iso	eng
dc.publisher	BMC
dc.relation.ispartofseries	Translational Neurodegeneration;13
dc.rights	Attribution 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.source	Scientia
dc.subject	Esclerosi lateral amiotròfica - Tractament
dc.subject	Esclerosi lateral amiotròfica - Aspectes genètics
dc.subject	Anomalies cromosòmiques
dc.subject	Proteïnes quinases - Inhibidors - Ús terapèutic
dc.subject	Rates (Animals de laboratori)
dc.subject.mesh	Amyotrophic Lateral Sclerosis
dc.subject.mesh	/drug therapy
dc.subject.mesh	Mutation
dc.subject.mesh	Protein-Serine-Threonine Kinases
dc.subject.mesh	/antagonists & inhibitors
dc.subject.mesh	Disease Progression
dc.subject.mesh	Mice
dc.title	GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1186/s40035-024-00441-w
dc.subject.decs	esclerosis lateral amiotrófica
dc.subject.decs	/farmacoterapia
dc.subject.decs	mutación
dc.subject.decs	proteína-serina-treonina cinasas
dc.subject.decs	/antagonistas & inhibidores
dc.subject.decs	progresión de la enfermedad
dc.subject.decs	ratas
dc.relation.publishversion	https://doi.org/10.1186/s40035-024-00441-w
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Ortiz DA, Peregrín N] DNA and RNA Medicine Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain. [Valencia M] Biomedical Engineering Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain. Institute of Data Science and Artifcial Intelligence (DATAI), University of Navarra, Pamplona, Spain. Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. [Vinueza Gavilanes R, Ferrero R] DNA and RNA Medicine Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain. Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. [Marín Ordovas E] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.identifier.pmid	39304897
dc.identifier.wos	001317459900001
dc.rights.accessrights	info:eu-repo/semantics/openAccess